Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

68.96 +1.44 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase 
Via The Motley Fool
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
Via The Motley Fool
3 Biotech Catalysts Present Major Opportunity
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further. 
Via MarketBeat
Top 2 Health Care Stocks That May Fall Off A Cliff In August
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
An Overview of Tarsus Pharmaceuticals's Earnings
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
 
Via Benzinga
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know
 
Via Benzinga
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights. 
Via Benzinga
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick?
Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS). 
Via Chartmill
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS)
A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). 
Via Chartmill
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Earnings Outlook For Tarsus Pharmaceuticals
 
Via Benzinga
Analyst Ratings For Tarsus Pharmaceuticals
 
Via Benzinga
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
 
Via Benzinga
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run
The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next. 
Via Investor's Business Daily
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Simple Ways To Stay With Trends: The Week In Charts
Has the market made its all-time highs? In this video I cover the stock and crypto markets. 
Via Talk Markets
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.